Valeant Pharma (VRX) Short Interest Rose 49% Before Citron's 'Smoking Gun'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Gilead Sciences (GILD) raises Revenue Guidance Following 3Q Beat; Maxim Group Reiterates Buy
October 28, 2015 1:47 PM EDTMaxim Group reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD), and raised the price target to $137.00 (from $129.00), following the company's 3Q earnings results. Gilead delivered a very strong quarter well ahead of street estimates. Gilead raised guidance for full year... More
Leerink PartnersRaises Price Target on Allergan (AGN) Following a MEDACorp Survey
October 28, 2015 7:05 AM EDTLeerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $342.00 (from $311.00), following a 60 person MEDACorp survey of US plastic surgeons and dermatologists. Specialists in the survey were bullish on Kybella and expect the drug to increase their submental fat patient... More
